INTERVENTION 1:	Intervention	0
Necitumumab Cohort 1 Day 3 Run-in	Intervention	1
day	UO:0000033	21-24
Necitumumab administered on Day 3 of the 3-week PK run-in period as an IV infusion at an absolute dose of 800 mg. Participants in Cohort 1 received necitumumab Process C drug product.	Intervention	2
day	UO:0000033	28-31
process	BFO:0000015	160-167
drug	CHEBI:23888	170-174
product	BAO:0003067	175-182
INTERVENTION 2:	Intervention	3
Necitumumab Cohort 1 Day 1, Cycle 1, Combination	Intervention	4
day	UO:0000033	21-24
Necitumumab administered on Days 1 and 8 of every 3-week cycle as an IV infusion at an absolute dose of 800 mg. Participants in Cohort 1 received necitumumab Process C drug product.	Intervention	5
process	BFO:0000015	158-165
drug	CHEBI:23888	168-172
product	BAO:0003067	173-180
Inclusion Criteria:	Eligibility	0
Have documented advanced or metastatic malignant solid tumors (except for colorectal tumors with KRAS mutation) that are resistant to standard therapy or for which no standard therapy is available	Eligibility	1
May have measurable or non-measurable disease	Eligibility	2
disease	DOID:4,OGMS:0000031	38-45
Have resolution to Grade 0 or 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE 4.0) of all clinically significant toxic effects (other than alopecia) of prior chemotherapy, surgery, radiotherapy, or hormonal therapy	Eligibility	3
cancer	DOID:162	48-54
alopecia	HP:0001596,DOID:987	197-205
surgery	OAE:0000067	230-237
radiotherapy	OAE:0000235	239-251
Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1	Eligibility	4
group	CHEBI:24433	37-42
Have adequate hepatic, hematologic and renal function	Eligibility	5
function	BAO:0003117,BFO:0000034	45-53
If female, are surgically sterile, postmenopausal, or agree to be compliant with a highly effective contraceptive method during and for 6 months after the treatment period. If male, are surgically sterile or agree to be compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period	Eligibility	6
female	PATO:0000383	3-9
male	CHEBI:30780,PATO:0000384	5-9
male	CHEBI:30780,PATO:0000384	176-180
Female participants of childbearing potential have a negative serum pregnancy test within 7 days prior to the first dose of study therapy	Eligibility	7
female	PATO:0000383	0-6
Exclusion Criteria:	Eligibility	8
Have received a systemic anticancer agent (including EGFR tyrosine kinase inhibitors) or device within 28 days prior to first dose of study therapy	Eligibility	9
tyrosine	CHEBI:18186	58-66
kinase	BAO:0000294	67-73
The most recent anticancer therapy received by the participant included either gemcitabine or cisplatin (or both)	Eligibility	10
gemcitabine	CHEBI:175901	79-90
cisplatin	CHEBI:27899	94-103
Have received radiotherapy within 14 days prior to first dose of study therapy	Eligibility	11
radiotherapy	OAE:0000235	14-26
Have received cytotoxic chemotherapy within 21 days prior to first dose of study therapy	Eligibility	12
Are receiving concurrent treatment with another anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy, chemoembolization, or targeted therapy	Eligibility	13
Are considered surgical candidates (with resectable disease)	Eligibility	14
disease	DOID:4,OGMS:0000031	52-59
Have brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants	Eligibility	15
brain	UBERON:0000955	5-10
Have narrowing of or blockage in large veins	Eligibility	16
Have coronary artery disease or uncontrolled congestive heart failure	Eligibility	17
coronary artery disease	DOID:3393	5-28
congestive heart failure	HP:0001635,DOID:6000	45-69
Have uncontrolled angina pectoris, or experienced myocardial infarction within 6 months prior to first dose of study therapy	Eligibility	18
angina pectoris	HP:0001681	18-33
myocardial infarction	HP:0001658,DOID:5844	50-71
Have an ongoing or active infection (requiring treatment), including active tuberculosis or known infection with the human immunodeficiency virus	Eligibility	19
active	PATO:0002354	19-25
active	PATO:0002354	69-75
tuberculosis	DOID:399	76-88
immunodeficiency	HP:0002721	123-139
virus	BAO:0000232	140-145
Have a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder	Eligibility	20
history	BFO:0000182	7-14
dementia	HP:0000726,DOID:1307	79-87
bipolar disorder	DOID:3312	102-118
Have known drug or alcohol abuse	Eligibility	21
drug	CHEBI:23888	11-15
alcohol	CHEBI:16236	19-26
If female, are pregnant or breastfeeding	Eligibility	22
female	PATO:0000383	3-9
Have had major surgery within 28 days prior to first dose of study medication or subcutaneous venous access device implantation within 7 days prior to first dose of study therapy	Eligibility	23
surgery	OAE:0000067	15-22
Are currently enrolled in, or discontinued within the 30 days prior to first dose of study therapy from a clinical trial involving an investigational product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study	Eligibility	24
product	BAO:0003067	150-157
drug	CHEBI:23888	182-186
Outcome Measurement:	Results	0
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab	Results	1
drug	CHEBI:23888	40-44
cmax	BAO:0002119	60-64
[Not Specified]	Results	2
Time frame: Run-In Period Day 3 Cohort 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 Hour (h) Post Start of Infusion; Cycle 1, Day 1: 0, 0.83, 1.33, 1.83, 3.83, 7.5, 24.83, 72 and 168 h Post Start of Infusion	Results	3
time	PATO:0000165	0-4
day	UO:0000033	26-29
day	UO:0000033	134-137
hour	UO:0000032	92-96
Results 1:	Results	4
Arm/Group Title: Necitumumab Cohort 1 Day 3 Run-in	Results	5
day	UO:0000033	38-41
Arm/Group Description: Necitumumab administered on Day 3 of the 3-week PK run-in period as an IV infusion at an absolute dose of 800 mg. Participants in Cohort 1 received necitumumab Process C drug product.	Results	6
day	UO:0000033	51-54
process	BFO:0000015	183-190
drug	CHEBI:23888	193-197
product	BAO:0003067	198-205
Overall Number of Participants Analyzed: 18	Results	7
Geometric Mean (Geometric Coefficient of Variation)	Results	8
mean	BAO:0002173	10-14
coefficient of variation	BAO:0000531	26-50
Unit of Measure: microgram/milliliter (ug/mL)  277        (22%)	Results	9
Results 2:	Results	10
Arm/Group Title: Necitumumab Cohort 1 Day 1, Cycle 1, Combination	Results	11
day	UO:0000033	38-41
Arm/Group Description: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an IV infusion at an absolute dose of 800 mg. Participants in Cohort 1 received necitumumab Process C drug product.	Results	12
process	BFO:0000015	181-188
drug	CHEBI:23888	191-195
product	BAO:0003067	196-203
Overall Number of Participants Analyzed: 12	Results	13
Geometric Mean (Geometric Coefficient of Variation)	Results	14
mean	BAO:0002173	10-14
coefficient of variation	BAO:0000531	26-50
Unit of Measure: microgram/milliliter (ug/mL)  315        (23%)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 5/18 (27.78%)	Adverse Events	1
Anaemia 1/18 (5.56%)	Adverse Events	2
Febrile neutropenia 1/18 (5.56%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Pancytopenia 0/18 (0.00%)	Adverse Events	4
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 1/18 (5.56%)	Adverse Events	5
thrombocytopenia	HP:0001873,DOID:1588	0-16
Acute myocardial infarction 1/18 (5.56%)	Adverse Events	6
acute myocardial infarction	DOID:9408	0-27
Eye pain 1/18 (5.56%)	Adverse Events	7
eye	UBERON:0000970	0-3
pain	HP:0012531	4-8
Diarrhoea 1/18 (5.56%)	Adverse Events	8
Intestinal obstruction 1/18 (5.56%)	Adverse Events	9
intestinal obstruction	HP:0005214,DOID:8437	0-22
Nausea 0/18 (0.00%)	Adverse Events	10
nausea	HP:0002018	0-6
Small intestinal obstruction 0/18 (0.00%)	Adverse Events	11
intestinal obstruction	HP:0005214,DOID:8437	6-28
Asthenia 0/18 (0.00%)	Adverse Events	12
asthenia	HP:0025406	0-8
Pyrexia 1/18 (5.56%)	Adverse Events	13
Adverse Events 2:	Adverse Events	14
Total: 8/17 (47.06%)	Adverse Events	15
Anaemia 0/17 (0.00%)	Adverse Events	16
Febrile neutropenia 0/17 (0.00%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	8-19
Pancytopenia 1/17 (5.88%)	Adverse Events	18
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 0/17 (0.00%)	Adverse Events	19
thrombocytopenia	HP:0001873,DOID:1588	0-16
Acute myocardial infarction 0/17 (0.00%)	Adverse Events	20
acute myocardial infarction	DOID:9408	0-27
Eye pain 0/17 (0.00%)	Adverse Events	21
eye	UBERON:0000970	0-3
pain	HP:0012531	4-8
Diarrhoea 0/17 (0.00%)	Adverse Events	22
Intestinal obstruction 0/17 (0.00%)	Adverse Events	23
intestinal obstruction	HP:0005214,DOID:8437	0-22
Nausea 1/17 (5.88%)	Adverse Events	24
nausea	HP:0002018	0-6
Small intestinal obstruction 1/17 (5.88%)	Adverse Events	25
intestinal obstruction	HP:0005214,DOID:8437	6-28
Asthenia 1/17 (5.88%)	Adverse Events	26
asthenia	HP:0025406	0-8
Pyrexia 0/17 (0.00%)	Adverse Events	27
